EXOMIND & rTMS Research Library
A recent systematic review found that active rTMS probably made little to no difference to PTSD severity compared with sham treatment in its primary analysis, although broader sensitivity analyses showed substantial variation across studies.
Why honest evidence matters
People living with PTSD deserve clear information, especially when a treatment is being considered. The primary analysis did not show a reliable advantage over sham treatment, so EXOMIND should not be marketed as an established PTSD treatment on the basis of this evidence.
Research Spotlight
Evidence remains uncertain
- 3 primary-analysis studies
- 99 participants
- SMD −0.14
- Protocol heterogeneity
What the evidence suggests
The primary analysis included three studies and 99 participants and produced a standardized mean difference of −0.14, with a confidence interval crossing no effect. When additional studies were included, results remained heterogeneous.
What this could mean for you
This evidence supports an assessment-first approach. rTMS may still be discussed for comorbid depression or within emerging PTSD research, but it should not be marketed as an established stand-alone PTSD treatment.
A careful, individualized next step
Research informs—but does not replace—individual clinical judgment. We review symptoms, diagnosis, previous treatment, medications, contraindications, functional goals and the strength of evidence for the proposed protocol. A consultation does not guarantee that treatment will be recommended.
Start with clinical fit—not promises
A consultation can clarify the main treatment target, established options and whether neuromodulation has any appropriate adjunctive role.
Book a Consultation Explore the related Calgary service
Study citation
Brown et al. Repetitive transcranial magnetic stimulation for post-traumatic stress disorder in adults. PMID: 39092744.
View the original record on PubMed
Educational information only. Findings from pooled research do not predict individual outcomes and may involve devices or protocols that differ from EXOMIND.